Cargando…

Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study

Patients with non-transfusion-dependent thalassemia (NTDT) often develop iron overload that requires chelation to levels below the threshold associated with complications. This can take several years in patients with high iron burden, highlighting the value of long-term chelation data. Here, we repo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taher, Ali T., Porter, John B., Viprakasit, Vip, Kattamis, Antonis, Chuncharunee, Suporn, Sutcharitchan, Pranee, Siritanaratkul, Noppadol, Galanello, Renzo, Karakas, Zeynep, Lawniczek, Tomasz, Habr, Dany, Ros, Jacqueline, Zhu, Zewen, Cappellini, M. Domenica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2013
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3790249/ https://www.ncbi.nlm.nih.gov/pubmed/23775581 http://dx.doi.org/10.1007/s00277-013-1808-z

Ejemplares similares

Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients
por: Taher, Ali T, et al.
Publicado: (2013)

Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox
por: Taher, Ali T, et al.
Publicado: (2014)

Validation of a patient‐reported outcomes symptom measure for patients with nontransfusion‐dependent thalassemia (NTDT‐PRO(©))
por: Taher, Ali, et al.
Publicado: (2018)

Development of a patient‐reported outcomes symptom measure for patients with nontransfusion‐dependent thalassemia (NTDT‐PRO(©))
por: Taher, Ali, et al.
Publicado: (2018)

Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload
por: Taher, Ali, et al.
Publicado: (2009)

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes
por: Taher, Ali T, et al.
Publicado: (2016)

Psychometric evaluation of the NTDT-PRO questionnaire for assessing symptoms in patients with non-transfusion-dependent beta-thalassaemia
por: Taher, Ali T, et al.
Publicado: (2023)

S273: LONG-TERM ERYTHROID RESPONSE DATA FROM PATIENTS (PTS) WITH NON-TRANSFUSION-DEPENDENT ΒETA-THALASSEMIA (NTDT) RECEIVING LUSPATERCEPT IN THE BEYOND TRIAL
por: Taher, Ali T., et al.
Publicado: (2023)

Iron overload across the spectrum of non‐transfusion‐dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions
por: Porter, John B., et al.
Publicado: (2016)

Profile of Luspatercept in the Treatment of Anemia in Adults with Non-Transfusion-Dependent β-Thalassemia (NTDT): Design, Development and Potential Place in Therapy
por: Musallam, Khaled M, et al.
Publicado: (2023)

Review of disease-related complications and management in adult patients with thalassemia: A multi-center study in Thailand
por: Chuncharunee, Suporn, et al.
Publicado: (2019)

Thalassa
por: Leal, Antonio
Publicado: (2008)

An urgent need for improving thalassemia care due to the wide gap in current real-life practice and clinical practice guidelines
por: Ekwattanakit, Supachai, et al.
Publicado: (2021)

Update on the use of deferasirox in the management of iron overload
por: Taher, Ali, et al.
Publicado: (2009)

Patient preference for deferasirox film-coated versus dispersible tablet formulation: a sequential-design phase 2 study in patients with thalassemia
por: Viprakasit, Vip, et al.
Publicado: (2023)

Treating iron overload in patients with non-transfusion-dependent thalassemia
por: Taher, Ali T, et al.
Publicado: (2013)

Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy
por: Porter, J. B., et al.
Publicado: (2012)

Exjade® (deferasirox, ICL670) in the treatment of chronic iron overload associated with blood transfusion
por: Cappellini, Maria Domenica
Publicado: (2007)

Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia
por: Daar, Shahina, et al.
Publicado: (2009)

Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in β-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial
por: Porter, John, et al.
Publicado: (2012)

Long-Term Effectiveness, Safety, and Tolerability of Twice-Daily Dosing with Deferasirox in Children with Transfusion-Dependent Thalassemias Unresponsive to Standard Once-Daily Dosing
por: Buaboonnam, Jassada, et al.
Publicado: (2021)

Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: the ESCALATOR study
por: Taher, Ali, et al.
Publicado: (2009)

Changing patterns in the epidemiology of β‐thalassemia
por: Kattamis, Antonis, et al.
Publicado: (2020)

Achieving treatment goals of reducing or maintaining body iron burden with deferasirox in patients with β-thalassaemia: results from the ESCALATOR study
por: Taher, Ali, et al.
Publicado: (2011)

Untreated Anemia in Nontransfusion-dependent β-thalassemia: Time to Sound the Alarm
por: Musallam, Khaled M., et al.
Publicado: (2022)

Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias
por: Porter, John B, et al.
Publicado: (2011)

Kidney Tubular Damage Secondary to Deferasirox: Systematic Literature Review
por: Scoglio, Martin, et al.
Publicado: (2021)

Identification and key management of non-transfusion-dependent thalassaemia patients: not a rare but potentially under-recognised condition
por: Viprakasit, Vip, et al.
Publicado: (2014)

Importance of optimal dosing ≥30 mg/kg/d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with β-thalassaemia
por: Taher, Ali, et al.
Publicado: (2011)

Marital status and paternity in patients with Transfusion-Dependent Thalassemia (TDT) and Non Transfusion-Dependent Thalassemia (NTDT): an ICET - A survey in different countries
por: De Sanctis, Vincenzo, et al.
Publicado: (2019)

Integrating Stochastic and Deterministic Process in the Biogeography of N(2)-Fixing Cyanobacterium Candidatus Atelocyanobacterium Thalassa
por: Li, Liuyang, et al.
Publicado: (2021)

Deferasirox: Over a Decade of Experience in Thalassemia
por: Moukalled, Nour M., et al.
Publicado: (2018)

Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study
por: Porter, John, et al.
Publicado: (2008)

The Transcriptional Cycle Is Suited to Daytime N(2) Fixation in the Unicellular Cyanobacterium “Candidatus Atelocyanobacterium thalassa” (UCYN-A)
por: Muñoz-Marín, María del Carmen, et al.
Publicado: (2019)

Non-transfusion dependent hemoglobin E/β thalassemia had high prevalence of vitamin D deficiency than more severe patients who received regular blood transfusion and iron chelation therapy
por: Nakavachara, Pairunyar, et al.
Publicado: (2013)

Improved R2* liver iron concentration assessment using a novel fuzzy c-mean clustering scheme
por: Saiviroonporn, Pairash, et al.
Publicado: (2015)

Common Single Nucleotide Polymorphism of TMPRSS6, an Iron Regulation Gene, Associated with Variable Red Blood Cell Indices in Deletional α-Globin Genotypes
por: Suksangpleng, Thidarat, et al.
Publicado: (2022)

Justification of Universal Iron Supplementation for Infants 6–12 months in Regions with a High Prevalence of Thalassemia
por: Sinlapamongkolkul, Phakatip, et al.
Publicado: (2023)

Cardio-protective effect of regular transfusion in children with non-transfusion dependent thalassemia (NTDT): A cohort study
por: Al Senaidi, Khalfan, et al.
Publicado: (2022)

Hypersensitivity reaction with deferasirox
por: Sharma, Atul, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_m0j8adn7871e2tgoirtsvmm2t5